Outcomes and factors associated with mortality in patients with atrial fibrillation and heart failure: FARAONIC study

Juan José Gómez Doblas, José María Cepeda-Rodrigo, Rosa Agra Bermejo, Elvira Blanco Labrador, Maria Teresa Blasco, Margarita Carrera Izquierdo, Iñaki Lekuona, Alejandro Recio Mayoral, Carles Rafols, Nicolás Manito, Juan José Gómez Doblas, José María Cepeda-Rodrigo, Rosa Agra Bermejo, Elvira Blanco Labrador, Maria Teresa Blasco, Margarita Carrera Izquierdo, Iñaki Lekuona, Alejandro Recio Mayoral, Carles Rafols, Nicolás Manito

Abstract

Background: Heart failure (HF) and atrial fibrillation (AF) are common and coexistent conditions.

Hypothesis: To investigate the adverse events and mortality risk factors in patients with AF and HF treated with rivaroxaban in Spain.

Methods: Multicenter, prospective and observational study with a follow-up of 2 years, that included adults, with a diagnosis of nonvalvular AF and chronic HF, anticoagulated with rivaroxaban at least 4 months before being enrolled.

Results: A total of 672 patients from 71 Spanish centers were recruited, of whom 658 (97.9%) were included in the safety analysis and 552 (82.1%) in the per protocol analysis. At baseline, the mean age was 73.7 ± 10.9 years, 65.9% were male, 51.3% had HF with preserved ejection fraction and 58.7% were on New York Heart Association functional class II. CHA2 DS2 -VASc was 4.1 ± 1.5. During the follow-up, 11.6% of patients died and around one-quarter of patients were hospitalized or visited the emergency department, being HF worsening/progression the main cause (51.1%), with a 2.9% of thromboembolic events and 2.0% of acute coronary syndromes. Major bleeding occurred in 3.1% of patients, with 0.5% experiencing intracranial bleeding but no fatalities. Compliance with HF treatment was associated with a lower risk of death (hazard ratio: 0.092; 95% confidence interval: 0.03-0.31).

Conclusions: Among patients with HF and AF anticoagulated with rivaroxaban, incidences of thromboembolic or hemorrhagic complications were low. The most important factor for improving survival was compliance with HF drugs, what strengths the need for early treatment with HF disease-modifying therapy and anticoagulation.

Keywords: anticoagulation; atrial fibrillation; death; direct oral anticoagulant; heart failure; hemorrhage; rivaroxaban; thromboembolism; worsening heart failure.

© 2023 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

References

REFERENCES

    1. Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019;7:447-456.
    1. Skanes AC, Tang ASL. Atrial fibrillation and heart failure: untangling a modern gordian knot. Can J Cardiol. 2018;34:1437-1448.
    1. Anguita Sánchez M, Bertomeu Martínez V, Ruiz Ortiz M, et al. Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes del «mundo real» con fibrilación auricular no valvular. Estudio FANTASIIA. Rev Esp Cardiol. 2020;73:14-20.
    1. Barrios V, Escobar C, Prieto L, et al. Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España. Estudio PAULA. Rev Esp Cardiol. 2015;68:769-776.
    1. Escobar C, Varela L, Palacios B, et al. Características clínicas, manejo y riesgo de complicaciones a un año en pacientes con insuficiencia cardíaca con y sin diabetes tipo 2 en España. Rev Clin Esp. 2022;222:195-204.
    1. Escobar C, Varela L, Palacios B, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res. 2020;20:964.
    1. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation. 2003;107:2920-2925.
    1. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GYH. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660-666.
    1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498.
    1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
    1. van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013;6:740-747.
    1. Palamaner Subash Shantha G, Mentias A, Inampudi C, et al. Sex-specific associations of oral anticoagulant use and cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2017;6:e006381.
    1. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2010;137:263-272.
    1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138:1093-1100.
    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726.
    1. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemostasis. 2015;13:2119-2126.
    1. Dubner SJ, Teutsch C, Huisman MV, et al. Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF. ESC Heart Fail. 2020;7:2679-2689.
    1. Anguita Sánchez M, Marín F, Masjuan J, et al. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study. Cardiol J. 2022;29:936-947.
    1. Rywik TM, Doryńska A, Wiśniewska A, et al. Epidemiology and clinical characteristics of hospitalized heart failure patients with a reduced, mildly reduced and preserved ejection fraction. Pol Arch Intern Med. 2022;132:16227.
    1. Tan C, Dinh D, Brennan A, et al. Characteristics and clinical outcomes in patients with heart failure with preserved ejection fraction compared to heart failure with reduced ejection fraction: insights from the VCOR heart failure snapshot. Heart, Lung Circ. 2022;31:623-628.
    1. Butt JH, Docherty KF, Jhund PS, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022;24:513-525.
    1. Böhm M, Slawik J, Brueckmann M, et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2020;22:126-135.
    1. Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail. 2021;23:1300-1312.
    1. Miao B, Alberts MJ, Bunz TJ, Coleman CI. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls. J Thromb Thrombolysis. 2019;48:366-372.
    1. Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35:233-241.
    1. Pocock SJ, Ariti CA, McMurray JJV, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404-1413.
    1. Senni M, Parrella P, De Maria R, et al. Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. Int J Cardiol. 2013;163:206-211.
    1. Lopes RD, Pieper KS, Stevens SR, et al. Predicting outcomes over time in patients with heart failure, left ventricular systolic dysfunction, or both following acute myocardial infarction. J Am Heart Assoc. 2016;5:e003045.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe